Navigation Links
Medicines derived from cannabis: a review of adverse events
Date:6/16/2008

This release is available in French.

Montreal, 13 June 2008 Researchers at the McGill University Health Centre (MUHC), McGill University and the University of British Columbia (UBC) determined that medical use of cannabinoids do not cause an increase in serious adverse events, but are associated with an increase in some non-serious adverse events.

Several drugs containing compounds derived from the cannabis plant, or cannibinoids, are available for medical purposes in Canada. As the use of cannabinoid medications increases, so do concerns about their potential to cause "adverse events," or negative side effects. Dr. Mark Ware, Dr. Stan Shapiro and PhD candidate Tongtong Wang of the Research Institute of the McGill University Health Centre and McGill University, and Dr. Jean-Paul Collet of the University of British Columbia examined the nature of these potential adverse events in a study which will be published June 16 in the Canadian Medical Association Journal (CMAJ).

The study was based on the adverse events reported in 31 separate clinical studies of cannabinoid medications conducted between 1966 and 2007. Adverse events were categorized as either serious or non-serious; with serious adverse events defined as those leading to death, hospitalization or disability.

"Overall, we found an 86% increase in the rate of non-serious adverse events among the patients treated with cannabinoids compared to the patients in the control groups," said Ware, a neurosciences researcher at the Research Institute of the MUHC and assistant professor in anesthesia at McGill's Faculty of Medicine The majority of events were mild to moderate in severity.

The majority of non-serious adverse events observed affected the nervous system, mainly dizziness and drowsiness. "Cannabinoids are used as medicines because they are neurologically active, so we expected to see some side effects such as these," said Wang, a PhD candidate in epidemiology and biostatistics at McGill University.

Cannabinoids have been shown to treat chronic pain resulting from diseases such as cancer, multiple sclerosis, arthritis and fibromyalgia, and also to stimulate appetite and relieve nausea. Physicians must weigh the possible benefits of treatment against the possible side effects in an overall attempt to improve the patient's quality of life.

"We have summarized the adverse events from these studies to help educate physicians and patients about the possible risks of medical cannabinoids," said Collet, formerly at McGill's Department of Epidemiology, and now professor at University of British Columbia, senior researcher at the Child & Family Research Institute and Director of the Centre for Applied Health Research and Evaluation at British Columbia Children's Hospital. "We cannot extend these results to smoked cannabis or recreational use. That will require further research."


'/>"/>

Contact: Isabelle Kling
isabelle.kling@muhc.mcgill.ca
514-843-1560
McGill University Health Centre
Source:Eurekalert

Related biology news :

1. Human embryonic stem cell -- derived bone tissue closes massive skull injury
2. Curry-derived molecules might be too spicy for colorectal cancers
3. Geron Demonstrates hESC-derived cardiomyocytes improve heart function after myocardial infarction
4. Human derived stem cells can repair rat hearts damaged by heart attack
5. Stanford researchers publish review of US medical device regulation
6. Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
7. Faster koa tree growth without adverse ecosystem effects
8. Chemical compound prevents cancer in lab
9. Vobile Launches VideoDNA Live; Enables Real-Time Digital Content Protection for Live Broadcast Events
10. A compound extracted from olives inhibits cancer cells growth and prevents their appearance
11. Device prevents potential errors in childrens medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Calif. , March 21, 2017 ... analytics company serving law enforcement agencies, announced today the ... as director of public safety business development. ... diversified law enforcement experience, including a focus on the ... In his most recent position, Mr. Sheridan served as ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... enables to match face pictures against each other or against large databases. The ... ... fastest software for biometric Face Matching on the market. The speed is at ...
(Date:3/7/2017)... SALT LAKE CITY , March 7, 2017 /PRNewswire/ ... solutions that help top global companies identify the best ... Leonard as Chief Sales Officer (CSO) and ... and Kucer,s appointments round out a seasoned executive team poised ... year and beyond, building on a year of record ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... ... March 28, 2017 , ... ... MultiMountTM weigh modules. These weigh modules are designed according to European Hygienic ... (NSF). , As fully integrated weighing solutions, SWB805 MultiMount weigh modules reduce ...
(Date:3/27/2017)... , March 27, 2017 Roka Bioscience, Inc. ... testing solutions for the detection of foodborne pathogens,  today announced ... Sidoti & Company Spring 2017 Convention on March 29 at ... York Marriott Marquis. About Roka Bioscience ... Roka ...
(Date:3/27/2017)... 2017 Infectex Ltd., a Russian portfolio company of Maxwell Biotech ... SQ109 added to the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis ... ( USA ) and the US National Institutes of Health. ... ... Fund Logo ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... PMG ... Trial Collaborations (CTC) conference presented by The Conference Forum in Boston on April ... they collaborate to drive improved clinical trial outcomes and bring them closer to the ...
Breaking Biology Technology: